Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury
Retrieved on:
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Renal replacement therapy, Risk, Acute kidney injury, AKI, China, Health, Review, Patient, GLOBE, Conference, Security (finance), SIX Swiss Exchange, Safety, Private Securities Litigation Reform Act, EST, Death, CKD, ISIN, Cardiopulmonary bypass, Nephrology, ROCK2, CYP11B2, MD, Fresenius Medical Care, Incidence, COVID-19, Degenerative disease, HGF, EGFR, GFR, NASDAQ, Glomerular filtration rate, Conditional sentence, Half-life, Hepatocyte growth factor, AUC, Odds ratio, Pharmaceutical industry, Medical imaging
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint.
Key Points:
- However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint.
- Topline results from the Phase 2 GUARD trial appear below.
- Angion and Vifor are evaluating the full data set from the Phase 2 GUARD trial in patients at risk for acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI).
- Angion and Vifor are evaluating the full data set from the ANG-3777 Phase 2 GUARD trial in patients at risk for acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI).